

REVIEW ARTICLE

Neutrophil gelatinase-associated lipocalin (NGAL) role in diagnosis of complications of liver cirrhosis

¹Dalia K. Nassar*, ¹Mohamed F. Elkenawy, ¹Mohammed M. El-Naggar, ²El-Sayed A. Khalil, ¹Ghada I. Barakat

¹Medical Microbiology & Immunology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

²Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt

ABSTRACT

Key words:

NGAL, liver cirrhosis, AKI, ascites, spontaneous bacterial peritonitis.

***Corresponding Author:**

Dalia Kamal Nassar
Medical Microbiology &
Immunology Department,
Faculty of Medicine, Mansoura
University, Mansoura, Egypt
Tel.: 01006210518
dalianasser@mans.edu.eg

Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa glycoprotein that is normally expressed at very low levels in several human tissues. NGAL comprises a critical component of innate immunity to bacterial infection acting as an acute phase protein. Also, it is one of the most promising markers for diagnosis of kidney injury.

Abbreviations:

NGAL: Neutrophil gelatinase-associated lipocalin, **AKI:** acute kidney injury, **kDa:** Kilo Dalton, **ACLF:** acute on chronic liver failure, **LPS:** lipopolysaccharides, **TNF α :** tumor necrosis factor alpha, **SBP:** spontaneous bacterial peritonitis.

INTRODUCTION

Liver cirrhosis is defined as diffuse hepatic fibrosis with nodules replacing the normal liver architecture, causing disturbance of normal physiology of the liver. Cirrhosis is associated with high mortality rates and particularly affects persons in the most productive years of their lives¹.

The major complications of liver cirrhosis include ascites, hepatic encephalopathy, hepatocellular carcinoma, bacterial infections and acute kidney injury (AKI), of which the latter two are commonly associated with mortality in patients with cirrhosis^{2,3}.

NGAL nomenclature and production

NGAL belongs to the lipocalin family that has gained wide attention from scientists in the past few years⁴. It is stored in the secondary granules of neutrophils^{4,5}.

NGAL is normally expressed in bone marrow, liver, lung and kidney. There is a low baseline production of NGAL that maintains its serum concentration to around 20 ng/ mL⁵. These normal levels of circulating NGAL are due to glomerular filtration as it possesses low molecular weight and positive charge⁶.

NGAL is overexpressed in several tissues in response to tissue injury^{7,8}. Urine NGAL is secreted from damaged kidney tubules⁹. Induced expression of NGAL is achieved through the binding of activated

nuclear factor NF- κ B to the promoter region of the NGAL gene¹⁰. Moreover, marked NGAL secretion occurs in human cancerous tissues due to induction of NGAL gene by tumor-promoting agents as polyoma virus, hepatocyte growth factor and transforming factor Neu¹¹.

NGAL structure

NGAL is a 25-kDa protein that is encoded by lipocalin-2 gene¹². The gene contains 7 exons encoding for 5 functional transcripts⁵.

Lipocalin family functions as transporter proteins that act by binding ligands and delivering small molecules to target cells. They are involved in many processes such as regulation of cell growth and immune response, transport of retinol and synthesis of prostaglandin¹³.

Lipocalin family are present in prokaryotes and eukaryotes¹⁴. Lipocalins are quite diverse sharing only about 20% of sequence homology. However, they all have structurally conserved regions encoding a common tertiary structure called the lipocalin folds which compromise an 8 anti-parallel β -sheets enclosing a hydrophobic cavity for ligand binding¹⁵.

Seven short loops (L1–L7) connect the β -sheets together. Also, the lipocalin fold compromises 3–10 helices at the N- terminus and an α - helix at the C-terminus. Various ligands can bind lipocalin fold in different members of lipocalin family due to different amino acids within the fold¹² (figure 1).




Fig. 1: Schematic representation of the lipocalin fold¹². Blue boxed regions: structurally conserved region between different lipocalins, Black boxed region shows significant conservation in amino acid sequence.

Ligands for NGAL: Siderophores

Goetz et al.¹³ reported that NGAL ligand is siderophores after studying X-ray crystallography of recombinant NGAL expression in *E. coli*. Siderophores are a group of iron binding chemicals that is produced in bacteria and fungi¹⁶.

NGAL Expression and Induction

NGAL is an acute phase reactant that is rapidly induced by tissue damage¹⁷. Its increased expression occurs within few hours from toxic insults. This property of rapid and intense expression is of major value in identifying patients at risk of developing tissue damage⁶. Inducers of NGAL include IL-1 β , LPS, TNF α , prostaglandin F2 α and hypoxia¹⁸.

NGAL rapidly increases in blood and urine in acute kidney disease¹⁹. Moreover, NGAL expression was reported to increase in case of bowel and respiratory inflammation^{12,20}.

Functions of NGAL

NGAL exerts many activities by binding to siderophores⁴. Enterochelin is a siderophore produced by bacteria that has high affinity to iron to provide bacteria with intracellular iron stores. So, it binds iron in the extracellular space and the siderophore-iron

complex is delivered back to bacteria by specific transporters^{21,22}.

NGAL binds siderophores by ionic interactions between positively charged amino acids of NGAL pocket and negatively charged siderophores' side chains²³. Thus, NGAL exerts a bacteriostatic function by capturing and depleting these siderophores consequently depleting the bacterial iron stores and preventing their growth^{21,22}.

This bacteriostatic role has been confirmed by studies on knockout mice without both copies of the NGAL gene. Comparing those animals with their wild-type counterparts, they were more susceptible to bacterial infections with higher mortality rate due to sepsis²⁴.

Therefore, NGAL is considered a critical element of innate immune response to exogenous bacterial infections⁴.

Moreover, NGAL is responsible for apoptosis of pro-B cells and inhibition and erythropoiesis by chelating iron^{25,26}. The mammalian siderophores are used by NGAL to provide cells with iron as iron plays an important role in regulation of cell cycle activities²⁷.

As for its role in promoting tumorigenesis, NGAL expression within carcinoma cells represents a poor

prognostic element, meanwhile its decreased expression delays tumorigenesis⁴. Zhang et al²⁸ concluded that NGAL is responsible for survival of tumor cell, enhanced cell proliferation and metastatic spread.

Mechanism of action of NGAL

NGAL binds with specific surface receptors as 24p3R which are present on surface of the kidney tubules²⁹.

Upon binding these receptors, NGAL enters the cell in one of two forms; Apo-NGAL (protein alone) or Holo-NGAL (NGAL-iron-siderophores complex (figure 2)¹⁷.

Holo-NGAL is transported through the cytoplasm within endosomal vesicles and it regulates the activity of iron-dependent genes by releasing the siderophore-iron complex. Upon Apo-NGAL entry, it depletes intracellular stores of iron¹⁷.




Fig. 2: Schematic model of the functions of NGAL¹⁷

NGAL role in liver diseases

It is not clear which cell types are primarily responsible for elevated serum NGAL, given that many cell types have been shown to produce it⁸. Serum NGAL expression increased in hepatocytes in patients with acute on chronic liver failure (ACLF)³⁰.

NGAL as a biomarker for infection

NGAL has been evaluated in diagnosis of infection in several studies. Guiddir et al³¹ reported higher cerebrospinal NGAL levels in acute bacterial meningitis in comparison to viral meningitis.

Also, NGAL can distinguish between bacterial and non-bacterial peritonitis in peritoneal dialysis patients³². Cullaro et al³³ found that ascites NGAL in cirrhotic patients was higher in spontaneous bacterial peritonitis (SBP) than control patients suggesting that NGAL levels is a sensitive and specific biomarker for diagnosis of SBP. Moreover, serum NGAL was higher in septic than non-septic patients³⁴.

NGAL as a biomarker for AKI

Transcriptome profiling and proteomic studies have identified NGAL as ‘ready to go gene’ that is highly

induced and rapidly expressed upon sensing stress and/or kidney damage³⁵.

NGAL is regarded as an acute phase reactant such as IL-6 and C-reactive protein. NGAL protein was reported to increase up to 1000 fold in severe cases of AKI¹⁶.

The discovery that urine NGAL was detected in experimental animals soon after AKI has encouraged conducting translational studies to assess its role in human AKI³⁶.

As NGAL is rapidly secreted from the nephron, its level increases 48 hours before serum creatinine changes³⁷. Moreover, NGAL can detect subclinical or modest renal damage without significant variations in serum creatinine³⁸.

CONCLUSION

NGAL is an acute phase reactant that is induced in infection, injury and inflammation. It can be a valuable marker for diagnosis of multiple complication of liver cirrhosis as AKI and bacterial infection.

- The authors declare that they have no financial or nonfinancial conflicts of interest related to the work done in the manuscript.
- Each author listed in the manuscript had seen and approved the submission of this version of the manuscript and takes full responsibility for it.
- This article had not been published anywhere and is not currently under consideration by another journal or a publisher.

REFERENCES

1. Kamath PS, Shah, VH. Chapter 74: Overview of cirrhosis. In: Feldman M, Friedman LS, Brandt LJ, editors. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease E-Book: Pathophysiology, Diagnosis, Management*, Philadelphia: Elsevier; 2020, p. 1164-1171.
2. Chirapongsathorn S, Krittanawong C, Enders FT, Pendegraft R, Mara KC, Borah BJ, et al. Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis. *Hepatology communications*. 2018;2(2):188–198.
3. Sharma P, Schaubel DE, Gong Q, Guidinger M, Merion RM. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. *Hepatology*. 2012;55(1):192–198.
4. Makris K, Rizos D, Kafkas N, Haliassos A. Neutrophil gelatinase-associated lipocalin as a new biomarker in laboratory medicine. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2012;50(9):1519–1532.
5. Virzi GM, Clementi A, de Cal M, Cruz DN, Ronco C. Genomics and biological activity of neutrophil gelatinase-associated lipocalin in several clinical settings. *Blood purification*. 2013;35(1–3):139–143.
6. Paragas N, Qiu A, Hollmen M, Nickolas TL, Devarajan P, Barasch J. NGAL-Siderocalin in kidney disease. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*. 2012;1823(9):1451–1458.
7. Ariza X, Graupera I, Coll M, Solà E, Barreto R, García E, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. *Journal of hepatology*. 2016;65(1):57–65.
8. Xu M-J, Feng D, Wu H, Wang H, Chan Y, Kolls J, et al. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. *Hepatology*. 2015;61(2):692–702.
9. Devarajan P. NGAL for the detection of acute kidney injury in the emergency room. *Biomarkers in medicine*. 2014;8(2):217–219.
10. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. *Genomics*. 1997;45(1):17–23.
11. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. *Biomarkers in Medicine*. 2010;4(2):265–280.
12. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. *Biochim Biophys Acta*. 2012 Aug;1826(1):129–169.
13. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. *Molecular cell*. 2002;10(5):1033–1043.
14. Ganfornina MD, Gutiérrez G, Bastiani M. A phylogenetic analysis of the lipocalin protein family. *Molecular biology and evolution*. 2000;17(1):114–126.
15. Grzyb J, Latowski D, Strzałka K. Lipocalins—a family portrait. *Journal of plant physiology*. 2006;163(9):895–915.
16. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. *The Journal of clinical investigation*. 2005;115(3):610–621.

17. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. *Clin Chem Lab Med*. 2012 Feb 15;50(9):1505–1517.
18. Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 β , but not by TNF- α . *The Journal of Immunology*. 2003;171(12):6630–6639.
19. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *The Lancet*. 2005;365(9466):1231–1238.
20. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. *Kidney Int*. 2007 May;71(10):967–970.
21. Clifton MC, Corrent C, Strong RK. Siderocalins: siderophore-binding proteins of the innate immune system. *BioMetals*. 2009 Aug;22(4):557–564.
22. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual action of neutrophil gelatinase-associated lipocalin. *Journal of the American Society of Nephrology*. 2007;18(2):407–413.
23. Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. *Biometals*. 2006 Apr;19(2):211–215.
24. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to *Escherichia coli* infection but not to ischemia-reperfusion injury. *Proceedings of the National Academy of Sciences*. 2006;103(6):1834–1839.
25. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. *Cell*. 2005;123(7):1293–1305.
26. Miharada K, Hiroshima T, Sudo K, Nagasawa T, Nakamura Y. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. *The FASEB journal*. 2005;19(13):1881–1883.
27. Bao G-H, Ho C-T, Barasch J. The ligands of neutrophil gelatinase-associated lipocalin. *RSC advances*. 2015;5(126):104363–104374.
28. Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. *Cancer epidemiology*. 2012;36(5):e294–299.
29. Devireddy LR, Gazin C, Zhu X, Green MR. A Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake. *Cell*. 2005;123(7):1293–1305.
30. Lu J, Lin L, Ye C, Tao Q, Cui M, Zheng S, et al. Serum NGAL Is Superior to Cystatin C in Predicting the Prognosis of Acute-on-Chronic Liver Failure. *Annals of hepatology*. 2019; 18(1):155-164.
31. Guiddir T, Deghmane A-E, Giorgini D, Taha M-K. Lipocalin 2 in cerebrospinal fluid as a marker of acute bacterial meningitis. *BMC Infectious Diseases*. 2014 May;14(1):276.
32. Martino FK, Filippi I, Giavarina D, Kaushik M, Rodighiero MP, Crepaldi C, et al. Neutrophil gelatinase-associated lipocalin in the early diagnosis of peritonitis: the case of neutrophil gelatinase-associated lipocalin. *Contributions to nephrology*. 2012;178:258–263.
33. Cullaro G, Kim G, Pereira MR, Brown RS, Verna EC. Ascites Neutrophil Gelatinase-Associated Lipocalin Identifies Spontaneous Bacterial Peritonitis and Predicts Mortality in Hospitalized Patients with Cirrhosis. *Dig Dis Sci Digestive Diseases and Sciences*. 2017;62(12):3487–3494.
34. Lentini P, de Cal M, Clementi A, D'Angelo A, Ronco C. Sepsis and AKI in ICU Patients: The Role of Plasma Biomarkers. *Critical Care Research and Practice Critical Care Research and Practice*. 2012;2012:1–5.
35. Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM. Biomarkers in acute kidney injury - pathophysiological basis and clinical performance. *Acta Physiol (Oxf)*. 2017 Mar;219(3):554–572.
36. Devarajan P. Neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. *Nephrology*. 2010;15(4):419–428.
37. Damman K, Chuen MJNK, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. *Journal of the American College of Cardiology*. 2011;57(22):2233–2241.
38. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. *Journal of the American College of Cardiology*. 2011; 57(17):1752–1761.